|
May 12, 2026
Today, the U.S. Food and Drug Administration conditionally approved Liavium-CA1 (pregabalin chewable tablets) for the management of pain and clinical signs associated with Chiari-like malformation and syringomyelia in dogs.
Chiari-like malformation (CM) is a genetic condition where a dog’s skull is too small for its brain. This malformation forces the cerebellum at the back of the brain to squeeze out through the base of the skull. Syringomyelia occurs when this squeezing restricts the flow of cerebrospinal fluid, causing painful fluid-filled pockets (syrinxes) on the spinal cord. These pockets swell and compress nerve fibers in the spinal cord, causing pain or discomfort.
The conditional approval means the FDA has determined Liavium-CA1 is safe and has a reasonable expectation of effectiveness for its intended use. The sponsor, TriviumVet, based in Ireland, has up to five years to generate the additional effectiveness data needed to support a full FDA approval.
You are subscribed to updates from FDA's Center for Veterinary Medicine.
|
